Benefits Think

How to manage the multimorbidity and costs of MSK pain

stock.adobe

If we want to move the needle on healthcare costs, we need to start with a key driver of those expenses: musculoskeletal (MSK) pain and dysfunction.

While many advisers and plan sponsors have implemented population health strategies that target metabolic syndrome and diabetes, a PBM solution or mental health, all require significant financial investments that can yield tepid results.

What these programs have in common is the need for physical activity and movement to achieve desired results. But if employees have MSK pain that's preventing this from happening, then they are just another expense and symptom-based band-aid with a big cost. 

Most of us will experience, at some point, what it's like to have pain limit our movement. The likelihood grows with age with the onset of osteoarthritis, low back pain, or both, two of the most disabling conditions.

Painful MSK conditions severely hamper people's potential to modify their lifestyle, lessening the negative effects of obesity, heart disease, cancer, arthritis and diabetes common to many Americans. A correlation between such conditions and decreased capacity to engage in physical activity is clearly evident. This leads to decreased functionality, frailty, diminished well-being and independence.

Read more: Why digital health may be what people with MSK conditions need

More than half of all U.S. adults, an astonishing 124 million people, have reported suffering from an MSK medical condition. This surpasses the prevalence of the two most commonly reported health conditions: circulatory (such as heart disease, stroke and hypertension) and respiratory (including emphysema and chronic asthma). These statistics demonstrate the impact of MSK conditions on a large portion of the population and highlight the need for improved treatment options. 

People of working age who have MSK issues experience increased self-reported health issues, a greater need for healthcare and reduced activity, leading to poorer overall and mental health, as well as higher healthcare utilization. 

The U.S. Centers for Disease Control and Prevention warns that MSK disorders can lead to significant financial costs for employers, including absenteeism, reduced productivity and increased spending on healthcare, disability and workers' compensation. These so-called indirect costs can add up quickly, impacting the bottom line of any business. 

This notion of multimorbidity is shared by others such as the Movement is Life Caucus, which address it as a vicious cycle. It's also my experience taking care of MSK patients for more than 30 years. Many report these problems when pain exceeds six weeks. 

There is no escaping the prevalence and impact of MSK pain except by examining health plan design holistically to not only address cost, but also employee experience and engagement. It only gets worse with the current model. Yet in talking with hundreds of health benefit advisers and plan sponsors, few do much — if anything — to address this ubiquitous problem beyond typical care. Digital physical therapy, a surgical center of excellence bundle and reference-based pricing (RBP) are in short supply. And with 40% of working Americans in pain, typical care — even if less expensive — is not working.

Many may be unaware that this spreadsheet cost is likely a driver of other plan costs. I'll put it in simple terms: When we don't move, blood pressure gets worse, increasing the risk for progressive cardiovascular disease, heart attack and heart failure. Atrial fibrillation and stroke are on the other side of that coin.

Read more: New Aon partnerships take on musculoskeletal care and high healthcare costs

Diabetes also gets worse with glucose levels increasing, driving the need for more medication and insulin, adversely impacting kidney health, weight and progression toward dialysis. Pre-diabetes is already rearing its ugly head on 90 million Americans and accelerates during times of inactivity.

With inactivity, weight increases, which is known to exacerbate back and knee pain. Obesity is connected to at least a dozen different types of cancers, the top cost for many employers. Sleep also gets worse, which affects all other biological systems and increases risk for accidents, poor decision-making and missed work. 

Mental health is adversely impacted as well; people with both arthritis and chronic pain report triple the rates of anxiety and depression. The internal dialog is damaging as people worry about everything from livelihood and relationships to job security and disease progression. These conditions also erode an employee's relationships, family, financial security, social interactions and hobbies. People in pain can quickly become half a person. 

All of these conditions have one other thing in common: inflammation. Systemic inflammation fuels diabetes, dementia, cardiovascular disease and arthritis. It's a vicious cycle that cannot be addressed by fixing parts of the health plan. People in pain are high utilizers of healthcare, which affect the entire health plan spend. 

MSK pain will touch PBM, diabetes, mental health, ambulatory and hospital costs. RBP in these instances is reactionary to an underlying problem, leaving many people on the sidelines in pain and burdening the health plan with additional costs.  

Multiple studies show that common surgeries do not have adequate evidence to be better than conservative care or placebo and do not improve quality of life. We're beginning to see carriers take action with this knowledge and no longer pay for these low-value procedures as Aetna considers arthroscopic partial meniscectomy experimental and investigational for degenerative meniscal tears. While this move reduces waste, it creates a vacuum for some to find relief. 

Current conservative treatment for knee arthritis actually makes it worse with steroid injections accelerating the degenerative process, and increasing risks of infection after surgery. Non-steroidal anti-inflammatory drugs make knee arthritis worse and hasten degenerative changes. Hardly any of this information is new, which doctors know, but because insurance pays, we continue to do it. 

Read more: Global healthcare benefit costs expected to jump 10% in 2023

Is what we're offering and paying a good value for human health and plan sponsor money? At what point is knowing this and continuing to do it going to raise questions with ERISA and plan fiduciary for both the employer and their benefits adviser? When conservative care stops helping and current treatments are no longer the best option, what's next?

There's a compelling solution now available. Autologous, cell-based procedures using the patient's own blood platelets, also known as platelet-rich plasma, and bone marrow concentrate can replace the need for up to 70% of elective orthopedic surgeries. These needle-based procedures represent a new medical specialty called interventional orthopedics, which keep the patient whole and intact. They come with no facility fee, nor do they require anesthesia – both significant cost drivers in and of themselves. 

These procedures can significantly reduce costs on the top three surgeries (i.e., knees, spine and shoulders). A third-party validated cost-savings report shows a 49% reduction in cost with 126 orthopedic surgeries avoided. Some payers and self-funded employers are rapidly incorporating these treatments into orthopedic medical practices. 

The American Academy of Orthopedic Surgeons has stated that platelet-rich plasma is a better conservative treatment option than what they currently recommend for knee osteoarthritis. It should be noted that Tricare added PRP as an approved treatment for knee OA and tennis elbow in 2019. Additionally, PRP injections quadrupled in prevalence from 2010 to Q1.2020, with a projected increase in annual usage in this data set of 66% by 2030, with a concordant increase in payer coverage. 

Alternatives to elective orthopedic surgery are becoming more popular, demonstrating cost-savings value, reducing the need for surgery, down time, rehab and medication use. Patients are actively seeking them out, while physicians see the value and are offering these solutions on a daily basis. 

Self-funded employers are increasingly offering this type of solution, which provides their employees an option in care. The orthopedic care continuum and treatment options are expanding rapidly, with benefit advisers and employers finally catching on. Nearly 100 third-party administrators adjudicate thousands of claims per year for more than 1,300 employers that have added needle-based procedures to their health benefits. 

Implementing strategies to reduce the need for elective orthopedic surgery, improve pain and function, as well as minimize MSK multimorbidity, has the potential to significantly reduce costs to the entire health plan while simultaneously improving overall individual health.

For reprint and licensing requests for this article, click here.
Healthcare Healthcare plans
MORE FROM EMPLOYEE BENEFIT NEWS